UPTRAVI
As listed in the register: UPTRAVI
600 mcg · tablet
- Prescription only
- Blood, clotting and anaemia
- Active substance
- Selexipag
- Used in
- Blood, clotting and anaemia
- Made by
- Janssen Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (UPTRAVI). It describes the substance, not this exact product.
Selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin.
Selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag.
Oxidative metabolism, catalyzed mainly by CYP2C8 and to a smaller extent by CYP3A4, leads to the formation of hydroxylated and dealkylated products.
In a study in healthy subjects with radiolabeled selexipag, approximately 93% of radioactive drug material was eliminated in feces and only 12% in urine.
Similar exposures were observed in pediatric study patients after taking whole tablets with water, taking with soft food, and dispersing in apple or orange juice.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-28
Safety of the active substance
From the US prescribing label for the same active substance (UPTRAVI). It describes the substance, not this exact product.
- Hypersensitivity to the active substance or to any of the excipients.
- Concomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
- Concomitant use with strong CYP2C8 inhibitors.
- ( 4, 7.1, 12.3 ) Hypersensitivity to the active substance or to any of the excipients.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
Spain2 matching products
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Janssen Inc |
|---|---|
| Active substance | Selexipag |
| Used in | Blood, clotting and anaemia |
| Strength | 600 mcg |
| Form | tablet |
| Classification | B01AC27 · Blood, clotting and anaemia |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02451174 |
| DPD drug code | 93743 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
8 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.